Syndax Pharmaceuticals fell short of earnings expectations by $0.07, according to the report referenced by Investing.com. The company nevertheless reported revenue above analysts’ estimates.
The available report does not provide the company’s earnings per share, revenue figure, comparison period or additional financial details.
Investing.com’s accompanying risk warning notes that trading leveraged products, including contracts for difference, options, futures, spread betting and foreign exchange, can result in substantial losses. It also states that past performance does not guarantee future results and that investors should assess their financial situation, experience and risk tolerance before making investment decisions.
Sources: Investing.com News.